Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With ADHD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-01

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To explore the relationship of treatment-related changes in electrophysiology and those in metabolomics for identification of the underlying metabolic mechanisms for the electrophysiological effects of methylphenidate in children with ADHD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder

NCT01130467

Attention Deficit Disorders With Hyperactivity Attention Deficit Disorder Hyperkinetic Syndrome

UNKNOWN

Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD

NCT02074228

Attention-deficit/Hyperactivity Disorder

UNKNOWN PHASE4

The Metabolome Profiling and Pathway Analysis of ADHD

NCT02942225

Attention-deficit/Hyperactivity Disorder

COMPLETED

Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00409708

Attention Deficit Hyperactivity Disorder

COMPLETED PHASE2

Inhibition Control of Children and Adolescents With ADHD

NCT01677819

Attention Deficit Hyperactivity Disorder

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although the efficacy of methylphenidate in reducing the core symptoms of attentiondeficit/ hyperactivity disorder (ADHD) is well documented in clinical trials, no definite biomarker has been identified to differentiate responders from non-responders to methylphenidate treatment for children with ADHD. In addition, the neural and metabolic mechanisms underlying the therapeutic effects of methylphenidate remain to be elucidated. In this 4-year prospective project, the investigators will explore the effects of 12-week treatment with methylphenidate on the electrophysiology and metabolomics of children with ADHD to identify the biomarkers for predicting the clinical response to methylphenidate. In addition, the investigators will explore the metabolic mechanisms through which methylphenidate treatment may modulate the abnormality in the electrophysiology of children with ADHD.

Specific Aims:

1. To examine the differences in electrophysiology and metabolomics between children with ADHD and neurotypical controls.
2. To examine the differences in the change of electrophysiology and metabolomics after 12-week treatment with methylphenidate between responders and non-responders in children with ADHD.
3. To explore the relationship of treatment-related changes in electrophysiology and those in metabolomics for identification of the underlying metabolic mechanisms for the electrophysiological effects of methylphenidate in children with ADHD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Methylphenidate Metabolomics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ADHD GROUP

Subjects with clinical diagnosis of ADHD according to the DSM-V criteria

methylphenidate

Intervention Type DRUG

The patients with ADHD will receive 12-week treatment with methylphenidate.

TD GROUP

Typically development controls without lifetime diagnosis with ADHD

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

methylphenidate

The patients with ADHD will receive 12-week treatment with methylphenidate.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients, aged 6 to 18 years, meet the DSM-5 diagnostic criteria for ADHD.
* At baseline, patients have a Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) score greater than 4.
* Patients have a Full IQ (FIQ) score greater than 80.

* aged 6 to 18 years
* All of the neurotypical participants have no psychiatric disorder in lifetime according to the diagnostic criteria of DSM-5.

Exclusion Criteria

* Patients have a major psychiatric disorder, such as autism spectrum disorder, schizophrenia, affective disorders, or substance use disorders.
* Patients have a major disorder of central nervous system, such as epilepsy.
* Patients have a major systemic disease, such as diabetes mellitus or cardiovascular diseases.
* Patients have ever received any medication to treat the clinical symptoms of ADHD.
2. Neurotypical participants:

* participants have any disorder of central nervous system or major systemic disease
* participants have ever taken any psychotropic drug, or who have FIQ scores less than 80, will be excluded from the present study.

Minimum Eligible Age

6 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes